SEARCH

SEARCH BY CITATION

References

  • References to studies included in this review
  • Ahlgren 2009a {published data only}
  • Ahlgren C, Oden A, Toren K, Andersen O. Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurologica Scandinavica 2009;119(5):313-20.
  • Ahlgren 2009b {published data only}
  • Ahlgren C, Toren K, Oden A, Andersen O. A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology 2009;24(9):541-52.
  • Beck 1989 {published data only}
  • Beck M, Welsz-Malecek R, Mesko-Prejac M, Radman V, Juzbasic M, Rajninger-Miholic M, et al.Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards 1989;17(1):85-90.
  • Benjamin 1992 {published data only}
  • Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ 1992;304(6834):1075-8.
  • Bertuola 2010 {published data only}
  • Bertuola F, Morando C, Menniti-Ippolito F, Da Cas R, Capuano A, Perilongo G, et al.Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety 2010;33(1):65-72.
  • Black 1997 {published data only}
  • Black S, Shinefield H, Ray P, Lewis E, Chen R, Glasser J, et al.Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal 1997;16(5):500-3.
  • Black 2003 {published data only}
  • Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology 2003;55(1):107-11.
  • Bloom 1975 {published data only}
  • Bloom JL, Schiff GM, Graubarth H, Lipp RW Jr, Jackson JE, Osborn RL, et al.Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics 1975;87(1):85-7.
  • Bremner 2005 {published data only}
  • Bremner SA, Carey IM, DeWilde S, Richards N, Maier WC, Hilton SR, et al.Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood 2005;90(6):567-73.
  • Bremner 2007 {published data only}
  • Bremner SA, Carey IM, DeWilde S, Richards N, Maier WC, Hilton SR, et al.Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. Clinical and Experimental Allergy 2007;37(4):512-7.
  • Castilla 2009a {published data only}
  • Castilla J, Garcia Cenoz M, Arriazu M, Fernandez-Alonso M, Martinez-Artola V, Etxeberria J, et al.Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine 2009;27(15):2089-93.
  • Ceyhan 2001 {published data only}
  • Ceyhan M, Kanra G, Erdem G, Kanra B. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine 2001;19(31):4473-8.
  • Chamot 1998 {published data only}
  • Chamot E, Toscani L, Egger P, Germann D, Bourquin C. Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique 1998;46(2):100-7.
  • da Cunha 2002 {published data only}
  • da Cunha SS, Rodrigues LC, Barreto ML, Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine 2002;20(7-8):1106-12.
  • Davis 2001 {published data only}
  • Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, Mullooly J, et al.Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Archives of Pediatric and Adolescent Medicine 2001;155(3):354-9.
  • DeStefano 2002 {published data only}
  • DeStefano F, Gu D, Kramarz P, Truman BI, Iademarco MF, Mullooly JP, et al.Childhood vaccinations and risk of asthma. Pediatric Infectious Disease Journal 2002;21(6):498-504.
  • DeStefano 2004 {published data only}
  • DeStefano F, Bhasin TK, Thompson WW, Yeargin-Allsopp M, Boyle C. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics 2004;113(2):259-66.
  • Dourado 2000 {published data only}
  • Dourado I, Cunha S, Teixeira MG, Farrington CP, Melo A, Lucena R, et al.Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology 2000;151(5):524-30.
  • Dunlop 1989 {published data only}
  • Dunlop JM, RaiChoudhury K, Roberts JS, Bryett KA. An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health 1989;103(5):331-5.
  • Edees 1991 {published data only}
  • Edees S, Pullan CR, Hull D. A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health 1991;105(2):91-7.
  • Fombonne 2001 {published data only}
  • Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 2001;108(4):E58.
  • Fombonne 2006 {published data only}
  • Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006;118(1):e139-50.
  • France 2008 {published data only}
  • France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black SB, et al.Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008;121(3):e687-92.
  • Freeman 1993 {published data only}
  • Freeman TR, Stewart MA, Turner L. Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal 1993;149(11):1669-74.
  • Giovanetti 2002 {published data only}
  • Giovanetti F, Laudani E, Marinaro L, Dogliani MG, Giachelli V, Giachino G, et al.Evaluation of the effectiveness of mumps immunization during an outbreak [Valutazione dell'efficacia della vaccinazione contro la parotite durante un'epidemia]. L'igiene Moderna 2002;117(3):201-9.
  • Goncalves 1998 {published data only}
  • Goncalves G, De Araujo A, Monteiro Cardoso ML. Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro surveillance: European Communicable Disease Bulletin 1998;3(12):119-21.
  • Harling 2005 {published data only}
  • Harling R, White JM, Ramsay ME, Macsween KF, van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005;23(31):4070-4.
  • Honda 2005 {published data only}
  • Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines 2005;46(6):572-9.
  • Hviid 2004 {published data only}
  • Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. New England Journal of Medicine 2004;350(14):1398-404.
  • Hviid 2008 {published data only}
  • Hviid A, Melbye M. Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology 2008;168(11):1277-83.
  • Jonville-Bera 1996 {published data only}
  • Jonville-Bera AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and Pasteur-Merieux serums et vaccins. Pediatric Infectious Disease Journal 1996;15(1):44-8.
  • Lerman 1981 {published data only}
  • Lerman SJ, Bollinger M, Brunken JM. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics 1981;68(1):18-22.
  • Lopez Hernandez 2000 {published data only}
  • Lopez Hernandez B, Martin Velez RM, Roman Garcia C, Penalver Sanchez I, Lopez Rosique JA. An epidemic outbreak of mumps. A study of vaccinal efficacy [Brote epidemico de parotiditis. Estudio de la efectividad vacunal]. Atencion primaria/Sociedad Española de Medicina de Familia y Comunitaria 2000;25(3):148-52.
  • Ma 2005 {published data only}
  • Ma X, Does MB, Metayer C, Russo C, Wong A, Buffler PA. Vaccination history and risk of childhood leukaemia. International Journal of Epidemiology 2005;34(5):1100-9.
  • Mackenzie 2006 {published data only}
  • Mackenzie DG, Craig G, Hallam NF, Moore J, Stevenson J. Mumps in a boarding school: description of an outbreak and control measures. British Journal of General Practice 2006;56(528):526-9.
  • Madsen 2002 {published data only}
  • Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, et al.A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine 2002;347(19):1477-82.
  • Makela 2002 {published data only}
  • Makela A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002;110(5):957-63.
  • Makino 1990 {published data only}
  • Makino S, Sasaki K, Nakayama T, Oka S, Urano T, Kimura M, et al.A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children 1990;144(8):905-10.
  • Marin 2006 {published data only}
  • Marin M, Nguyen HQ, Langidrik JR, Edwards R, Briand K, Papania MJ, et al.Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clinical infectious Diseases 2006;42(3):315-9.
  • Marolla 1998 {published data only}
  • Marolla F, Baviera G, Cacciapuoti, Calia V, Cannavavo R, Clemente A, et al.A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente : studio sul campo]. Rivista Italiana Di Pediatria 1998;24(3):466-72.
  • McKeever 2004 {published data only}
  • McKeever TM, Lewis SA, Smith C, Hubbard R. Vaccination and allergic disease: a birth cohort study. American Journal of Public Health 2004;94(6):985-9.
  • Miller 1989 {published data only}
  • Miller C, Miller E, Rowe K, Bowie C, Judd M, Walker D. Surveillance of symptoms following MMR vaccine in children. Practitioner 1989;233(1461):69-73.
  • Miller 2005 {published data only}
  • Miller E, Andrews N, Grant A, Stowe J, Taylor B. No evidence of an association between MMR vaccine and gait disturbance. Archives of Disease in Childhood 2005;90(3):292-6.
  • Miller 2007 {published data only}
  • Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology 2007;165(6):704-9.
  • Mrozek-Budzyn 2010 {published data only}
  • Mrozek-Budzyn D, Kieltyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatric Infectious Disease Journal 2010;29(5):397-400.
  • Ong 2005 {published data only}
  • Ong G, Goh KT, Ma S, Chew SK. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections 2005;51(4):294-8.
  • Ong 2007 {published data only}
  • Ong G, Rasidah N, Wan S, Cutter J. Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal 2007;48(7):656-61.
  • Park 2004 {published data only}
  • Park T, Ki M, Yi SG. Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statistics in Medicine 2004;23(12):1871-83.
  • Peltola 1986 {published data only}
  • Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet 1986;1(8487):939-42.
  • Ray 2006 {published data only}
  • Ray P, Hayward J, Michelson D, Lewis E, Schwalbe J, Black S, et al.Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatric Infectious Disease Journal 2006;25(9):768-73.
  • Robertson 1988 {published data only}
  • Robertson CM, Bennett VJ, Jefferson N, Mayon-White RT. Serological evaluation of a measles, mumps, and rubella vaccine. Archives of Diseases of Children 1988;63(6):612-6.
  • Schlegel 1999 {published data only}
  • Schlegel M, Osterwalder JJ, Galeazzi RL, Vernazza PL. Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ 1999;319(7206):352.
  • Schwarz 1975 {published data only}
  • Schwarz AJ, Jackson JE, Ehrenkranz NJ, Ventura A, Schiff GM, Walters VW. Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children 1975;129(12):1408-12.
  • Seagroatt 2005 {published data only}
  • Seagroatt V. MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ 2005;330(7500):1120-1.
  • Sharma 2010 {published data only}
  • Sharma HJ, Oun SA, Bakr SS, Kapre SV, Jadhav SS, Dhere RM, et al.No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection 2010;16(4):347-52.
  • Smeeth 2004 {published data only}
  • Smeeth L, Cook C, Fombonne E, Heavey L, Rodrigues LC, Smith PG, et al.MMR vaccination and pervasive developmental disorders: a case-control study. Lancet 2004;364(9438):963-9.
  • Stokes 1971 {published data only}
  • Stokes JJ, Weibel RE, Villarejos VM, Arguedas JA, Buynak EB, Hilleman MR. Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA 1971;218(1):57-61.
  • Stowe 2009 {published data only}
  • Stowe J, Andrews N, Taylor B, Miller E. No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine 2009;27(9):1422-5.
  • Swartz 1974 {published data only}
  • Swartz TA, Klingberg W, Klingberg MA. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection 1974;2(3):115-7.
  • Taylor 1999 {published data only}
  • Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, et al.Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999;353(9169):2026-9.
  • Uchiyama 2007 {published data only}
  • Uchiyama T, Kurosawa M, Inaba Y. MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders 2007;37(2):210-7.
  • Vestergaard 2004 {published data only}
  • Vestergaard M, Hviid A, Madsen KM, Wohlfahrt J, Thorsen P, Schendel D, et al.MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004;292(3):351-7.
  • Ward 2007 {published data only}
  • Ward KN, Bryant NJ, Andrews NJ, Bowley JS, Ohrling A, Verity CM, et al.Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics 2007;120(2):314-21.
  • Weibel 1980 {published data only}
  • Weibel RE, Carlson AJ Jr, Villarejos VM, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proceedings of the Society for Experimental Biology and Medicine 1980;165(2):323-6.
  • References to studies excluded from this review
  • Akobeng 1999 {published data only}
  • Akobeng AK, Thomas AG. Inflammatory bowel disease, autism, and the measles, mumps, and rubella vaccine. Journal of Pediatric Gastroenterology and Nutrition 1999;28(3):351-2.
  • Andre 1984 {published data only}
  • Andre FE. Summary of clinical studies with the Oka live varicella vaccine produced by Smith Kline-RIT. Biken Journal 1984;27(2-3):89-98.
  • Anonymous 1982 {published data only}
  • Anonymous. Adverse effects of Virivac. Lakartidningen 1982;79(42):3822.
  • Anonymous 1997 {published data only}
  • Anonymous. Vaccination: news on precautions, contraindications, and adverse reactions. Consultant 1997;37(3):756-60.
  • Anonymous 1999 {published data only}
  • Anonymous. Incidence of measles vaccine-associated adverse events is low. Drugs & Therapy Perspectives 1999;14(11):13-6.
  • Anonymous 2004 {published data only}
  • Anonymous. Childhood vaccination does not increase the incidence of type 1 diabetes. Evidence-based Healthcare and Public Health 2004;8(5):286-7.
  • Aozasa 1982 {published data only}
  • Aozasa K, Nara H, Kotoh K, Watanabe Y, Sakai S, Honda M. Malignant histiocytosis with slow clinical course. Pathology, Research and Practice 1982;174(1-2):147-58.
  • Asaria 2008 {published data only}
  • Asaria P, MacMahon E. Measles in the United Kingdom: can we eradicate it by 2010?. BMJ 2006;333(7574):890-5.
  • Autret 1996 {published data only}
  • Autret E, Jonville-Bera AP, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after isolated or combined vaccination against measles, mumps and rubella [Purpura thrombopenique apres vaccination isolee ou associee contre la rougeole, la rubeole et les oreillons]. Therapie 1996;51(6):677-80.
  • Bakker 2001 {published data only}
  • Bakker W, Mathias R. Mumps caused by an inadequately attenuated measles, mumps and rubella vaccine. Canadian Journal of Infectious Diseases 2001;12(3):144-8.
  • Balraj 1995 {published data only}
  • Balraj V ME. Complications of mumps vaccines. Reviews in Medical Virology 1995;5(4):219-27.
  • Beck 1991 {published data only}
  • Beck SA, Williams LW, Shirrell MA, Burks AW. Egg hypersensitivity and measles-mumps-rubella vaccine administration. Pediatrics 1991;88(5):913-7.
  • Bedford 2010 {published data only}
  • Bedford HE, Elliman DA. MMR vaccine and autism. BMJ 2010;340:c655.
  • Beeler 1996 {published data only}
  • Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatric Infectious Disease Journal 1996;15(1):88-90.
  • Benjamin 1991 {published data only}
  • Benjamin CM, Silman AJ. Adverse reactions and mumps, measles and rubella vaccine. Journal of Public Health Medicine 1991;13(1):32-4.
  • Berger 1988a {published data only}
  • Berger R, Just M, Gluck R. Interference between strains in live virus vaccines. I: combined vaccination with measles, mumps and rubella vaccine. Journal of Biological Standardization 1988;16(4):269-73.
  • Berger 1988b {published data only}
  • Berger R, Just M. Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine. Journal of Biological Standardization 1988;16(4):275-9.
  • Berlin 1983 {published data only}
  • Berlin BS. Convulsions after measles immunisation. Lancet 1983;1(8338):1380.
  • Bernsen 2008 {published data only}
  • Bernsen RM, van der Wouden JC. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children. Pediatric Allergy and Immunology 2008;19(6):544-51.
  • Bhargava 1995 {published data only}
  • Bhargava I, Chhaparwal BC, Phadke MA, Irani SF, Chhaparwal D, Dhorje S, et al.Immunogenicity and reactogenicity of indigenously produced MMR vaccine. Indian PediatrIcs 1995;32(9):983-8.
  • Bonanni 2005 {published data only}
  • Bonanni P, Bechini A, Pesavento G, Boccalini S, Tiscione E, Graziani G, et al.Implementation of the plan for elimination of measles and congenital rubella infection in Tuscany: evidence of progress towards phase II of measles control. Journal of Preventive Medicine and Hygiene 2005;46(3):111-7.
  • Borchardt 2007 {published data only}
  • Borchardt SM, Rao P, Dworkin MS. Is the severity of mumps related to the number of doses of mumps-containing vaccine?. Clinical Infectious Diseases 2007;45(7):939-40.
  • Borgono 1973 {published data only}
  • Borgono JM, Greiber R, Solari G, Concha F, Carrillo B, Hilleman MR. A field trial of combined measles-mumps-rubella vaccine. Satisfactory immunization with 188 children in Chile. Clinical Pediatrics 1973;12(3):170-2.
  • Boxall 2008 {published data only}
  • Boxall N, Kubinyiova M, Prikazsky V, Benes C, Castkova J. An increase in the number of mumps cases in the Czech Republic, 2005-2006. Euro surveillance: European Communicable Disease Bulletin 2008;13(16):18842 [pii].
  • Brockhoff 2010 {published data only}
  • Brockhoff HJ, Mollema L, Sonder GJ, Postema CA, van Binnendijk RS, Kohl RH, et al.Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004. Vaccine 2010;28(17):2932-6.
  • Bruno 1997 {published data only}
  • Bruno G, Grandolfo M, Lucenti P, Novello F, Ridolfi B, Businco L. Measles vaccine in egg allergic children: poor immunogenicity of the Edmoston-Zagreb strain. Pediatric Allergy and Immunology 1997;8(1):17-20.
  • Buntain 1976 {published data only}
  • Buntain WL, Missall SR. Letter: Local subcutaneous atrophy following measles, mumps, and rubella vaccination. American Journal of Diseases of Children 1976;130(3):335.
  • Buynak 1969 {published data only}
  • Buynak EB, Weibel RE, Whitman JE Jr, Stokes J Jr, Hilleman MR. Combined live measles, mumps, and rubella virus vaccines. JAMA 1969;207(12):2259-62.
  • Cardenosa 2006 {published data only}
  • Cardenosa N, Dominguez A, Camps N, Martinez A, Torner N, Navas E, et al.Non-preventable mumps outbreaks in schoolchildren in Catalonia. Scandinavian Journal of Infectious Diseases 2006;38(8):671-4.
  • Castilla 2009b {published data only}
  • Castilla J, Fernandez Alonso M, Garcia Cenoz M, Martinez Artola V, Inigo Pestana M, Rodrigo I, et al.Resurgence of mumps in the vaccine era. Factors involved in an outbreak in Navarre, Spain, 2006-2007 [Rebrote de parotiditis en la era vacunal. Factores implicados en un brote en Navarra, 2006-2007]. Medicina Clínica 2009;133(20):777-82.
  • Chang 1982 {published data only}
  • Chang HH. Immunisation problems in measles, rubella and mumps. Journal of the Korean Medical Association 1982;25(9):801-6.
  • Chen 1991 {published data only}
  • Chen RT, Moses JM, Markowitz LE, Orenstein WA. Adverse events following measles-mumps-rubella and measles vaccinations in college students. Vaccine 1991;9(5):297-9.
  • Chen 2000 {published data only}
  • Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations. An epidemiological review. Paediatric Drugs 2000;2(4):273-90.
  • Cherian 2010 {published data only}
  • Cherian MP, Al-Kanani KA, Al Qahtani SS, Yesurathinam H, Mathew AA, Thomas VS, et al.The rising incidence of type 1 diabetes mellitus and the role of environmental factors - three decade experience in a primary care health center in Saudi Arabia. Journal of Pediatric Endocrinology and Metabolism 2010;23(7):685-95.
  • Chiodo 1992 {published data only}
  • Chiodo F. Effectiveness and security of the trivalent vaccine against measles, parotitis and rubella (MPR). Igiene Moderna 1992;97(Suppl 1):77-86.
  • Cinquetti 1994 {published data only}
  • Cinquetti S, Tonetto L, Portello A, Chermaz E, Sernagiotto F, De Noni R, et al.Adverse reactions following vaccination with two different types of measles mumps-rubella vaccine [Reazioni indesiderate a due diverse preparazioni di vaccine 'triplo' antimorbillo-parotite-rosolia]. Igiene Moderna 1994;101(6):793-800.
  • Contardi 1989 {published data only}
  • Contardi I. Clinical and immunologic valuation of a new triple measles, mumps and rubella vaccine. Giornale di Malattie Infettive e Parassitarie 1989;41(11):1106-7.
  • Contardi 1992 {published data only}
  • Contardi I, Lusardi C, Cattaneo GG. A comparative study of 3 different types of trivalent measles-mumps-rubella vaccine. Pediatria Medica e Chirurgica 1992;14(4):421-4.
  • Coplan 2000 {published data only}
  • Coplan P, Chiacchierini L, Nikas A, Shea J, Baumritter A, Beutner K, et al.Development and evaluation of a standardized questionnaire for identifying adverse events in vaccine clinical trials. Pharmacoepidemiology and Drug Safety 2000;9(6):457-71.
  • Coronado 2006 {published data only}
  • Coronado F, Musa N, El Tayeb el SA, Haithami S, Dabbagh A, Mahoney F, et al.Retrospective measles outbreak investigation: Sudan, 2004. Journal of Tropical Pediatrics 2006;52(5):329-34.
  • Cox 2009 {published data only}
  • Cox AR, McDowell S. A response to the article on the association between paracetamol/acetaminophen: use and autism by Stephen T. Schultz. Autism: The International Journal of Research and Practice 2009;13(1):123-4; author reply 124-5.
  • Curtale 2010 {published data only}
  • Curtale F, Perrelli F, Mantovani J, Atti MC, Filia A, Nicoletti L, et al.Description of two measles outbreaks in the Lazio Region, Italy (2006-2007). Importance of pockets of low vaccine coverage in sustaining the infection. BMC Infectious Diseases 2010;10:62.
  • Czajka 2009 {published data only}
  • Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine 2009;27(47):6504-11.
  • D'Argenio 1998 {published data only}
  • D'Argenio P, Citarella A, Manfredi Selvaggi MT, Arigliani R, Casani A, et al.Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. The Benevento and Compobasso Pediatrician's Network for the Control of Vaccine-Preventable Diseases. Vaccine 1998;16(8):818-22.
  • D'Souza 2000 {published data only}
  • D'Souza RM, Campbell-Lloyd S, Isaacs D, Gold M, Burgess M, Turnbull F, et al.Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. Communicable Diseases Intelligence 2000;24(2):27-33.
  • Dales 2001 {published data only}
  • Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA 2001;285(9):1183-5.
  • Dallaire 2009 {published data only}
  • Dallaire F, De Serres G, Tremblay FW, Markowski F, Tipples G. Long-lasting measles outbreak affecting several unrelated networks of unvaccinated persons. Journal of Infectious Diseases 2009;200(10):1602-5.
  • Dankova 1995 {published data only}
  • Dankova E, Domorazkova E, Skovrankova J, Vodickova M, Honzonova S, Stehlikova J, et al.Immune reactivity and risk of an undesirable response after vaccination. Ceskoslovenská Pediatrie 1995;50(9):515-9.
  • Dashefsky 1990 {published data only}
  • Dashefsky B, Wald E, Guerra N, Byers C. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. Pediatrics 1990;85(4 Pt 2):682-9.
  • Davis 1997 {published data only}
  • Davis RL, Marcuse E, Black S, Shinefield H, Givens B, Schwalbe J, et al.MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997;100(5):767-71.
  • Dayan 2008a {published data only}
  • Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, et al.Recent resurgence of mumps in the United States. New England Journal of Medicine 2008;358(15):1580-9.
  • Deforest 1986 {published data only}
  • Deforest A, Long SS, Lischner HW. Safety and efficacy of simultaneous administration of measles-mumps-rubella (MMR) with booster doses of diphtheria-tetanus-pertussis (TP) and trivalent oral poliovirus (OPV) vaccines. Developments in Biological Standardization 1986;65:111.
  • Deforest 1988 {published data only}
  • Deforest A, Long SS, Lischner HW, Girone JA, Clark JL, Srinivasan R, et al.Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics 1988;81(2):237-46.
  • De Laval 2010 {published data only}
  • De Laval F, Haus R, Spiegel A, Simon F. Lower long-term immunogenicity of mumps component after MMR vaccine. Pediatric Infectious Disease Journal 2010;29(11):1062-3.
  • DeStefano 2000 {published data only}
  • DeStefano F, Chen RT. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Journal of Pediatrics 2000;136(1):125-6.
  • Diaz-Ortega 2010 {published data only}
  • Diaz-Ortega JL, Bennett JV, Castaneda D, Vieyra JR, Valdespino-Gomez JL, de Castro JF. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR. Vaccine 2010;28(3):692-8.
  • Dobrosavljevic 1999 {published data only}
  • Dobrosavljevic D, Milinkovic MV, Nikolic MM. Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination. Journal of the European Academy of Dermatology and Venereology 1999;13(1):59-61.
  • Dominguez 2008 {published data only}
  • Dominguez A, Torner N, Barrabeig I, Rovira A, Rius C, Cayla J, et al.Large outbreak of measles in a community with high vaccination coverage: implications for the vaccination schedule. Clinical Infectious Diseases 2008;47(9):1143-9.
  • Doshi 2009 {published data only}
  • Doshi S, Khetsuriani N, Zakhashvili K, Baidoshvili L, Imnadze P, Uzicanin A. Ongoing measles and rubella transmission in Georgia, 2004-05: implications for the national and regional elimination efforts. International Journal of Epidemiology 2009;38(1):182-91.
  • Dos Santos 2002 {published data only}
  • Dos Santos BA, Ranieri TS, Bercini M, Schermann MT, Famer S, Mohrdieck R, et al.An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Revista Panamericana de Salud Pública 2002;12(4):240-6.
  • Dyer 2010a {published data only}
  • Dyer C. Wakefield was dishonest and irresponsible over MMR research, says GMC. BMJ 2010;340:c593.
  • Dyer 2010b {published data only}
  • Dyer C. Lancet retracts Wakefield's MMR paper. BMJ 2010;340:c696.
  • Ehrenkranz 1975 {published data only}
  • Ehrenkranz NJ, Ventura AK, Medler EM, Jackson JE, Kenny MT. Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization 1975;52(1):81-5.
  • Elphinstone 2000 {published data only}
  • Elphinstone P. The MMR question. Lancet 2000;356(9224):161.
  • Englund 1989 {published data only}
  • Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH Jr. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. Journal of Pediatrics 1989;114(1):37-44.
  • Farrington 1996 {published data only}
  • Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology 1996;143(11):1165-73.
  • Farrington 2001 {published data only}
  • Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001;19(27):3632-5.
  • Fitzpatrick 2007 {published data only}
  • Fitzpatrick M. The end of the road for the campaign against MMR. British Journal of General Practice 2007;57(541):679.
  • Fletcher 2001 {published data only}
  • Fletcher AP. MMR safety studies. Adverse Drug Reactions and Toxicological Reviews 2001;20(1):57-60.
  • Garrido L 1992 {published data only}
  • Garrido Lestache A, Martin Hernandez D. Triple virus vaccination: study of its efficacy and safety. Pediatrika 1992;12:42-7.
  • Geier 2004 {published data only}
  • Geier DA, Geier MR. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Medical Science Monitor 2004;10(3):PI33-9.
  • Gerber 2009 {published data only}
  • Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clinical Infectious Diseases 2009;48(4):456-61.
  • Goodson 2010 {published data only}
  • Goodson JL, Perry RT, Mach O, Manyanga D, Luman ET, Kitambi M, et al.Measles outbreak in Tanzania, 2006-2007. Vaccine 2010;28(37):5979-85.
  • Griffin 1991 {published data only}
  • Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W. Risk of seizures after measles-mumps-rubella immunization. Pediatrics 1991;88(5):881-5.
  • Grilli 1992 {published data only}
  • Grilli G, Cimini D, Vacca F. Vaccination against measles, mumps and rubella: incidence of side effects using different vaccine strains. Giornale di Malattie Infettive e Parassitarie 1992;44(1):38-42.
  • Hilton 2009 {published data only}
  • Hilton S, Hunt K, Langan M, Hamilton V, Petticrew M. Reporting of MMR evidence in professional publications: 1988-2007. Archives of Disease in Childhood 2009;94(11):831-3.
  • Hindiyeh 2009 {published data only}
  • Hindiyeh MY, Aboudy Y, Wohoush M, Shulman LM, Ram D, Levin T, et al.Characterization of large mumps outbreak among vaccinated Palestinian refugees. Journal of Clinical Microbiology 2009;47(3):560-5.
  • Hornig 2008 {published data only}
  • Hornig M, Briese T, Buie T, Bauman ML, Lauwers G, Siemetzki U, et al.Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. PLoS ONE 2008;3(9):e3140.
  • Hu 2007 {published data only}
  • Hu JY, Tao LN, Shen J, Wang YC. Study on the epidemiological characteristics of rubella from 1990-2006 in Shanghai. Zhonghua Liu Xing Bing Xue Za Zhi 2007;28(7):645-8.
  • Hua 2009 {published data only}
  • Hua W, Izurieta HS, Slade B, Belay ED, Haber P, Tiernan R, et al.Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatric Infectious Disease Journal 2009;28(11):943-7.
  • Huang 1990 {published data only}
  • Huang LM, Lee CY, Hsu CY, Huang SS, Kao CL, Wu FF. Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine. Pediatric Infectious Disease Journal 1990;9(7):461-5.
  • Ipp 2003 {published data only}
  • Ipp M, Cohen E, Goldbach M, McArthur C. Pain response to measles-mumps-rubella (MMR) vaccination at 12 months of age: a randomised clinical trial. Journal of Paediatrics and Child Health 2003;39(6):A3.
  • Jiang 2009 {published data only}
  • Jiang Y, Pang H. Surveillance of adverse events following immunization of MMR in Changning District of Shanghai. Zhongguo Ji Hua Mian Yi 2009;15(6):496-7, 526.
  • Jones 1991 {published data only}
  • Jones AG, White JM, Begg NT. The impact of MMR vaccine on mumps infection in England and Wales. CDR (London, England: review) 1991;1(9):R93-6.
  • Just 1985 {published data only}
  • Just M, Berger R, Gluck R, Wegmann A. Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella [Feldversuch mit einer neuartigen Humandiploidzellvakzine (HDCV) gegen Masern, Mumps und Roteln]. Schweizerische Medizinische Wochenschrift 1985;115(48):1727-30.
  • Just 1986 {published data only}
  • Just M, Berger R, Just V. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Developments in Biological Standardization 1986;65:85-8.
  • Just 1987a {published data only}
  • Just M, Berger R. Immunogenicity of vaccines. A comparative study of a mumps-measles-rubella vaccine given with or without oral polio vaccine [Immunantwort auf Impstoffe. Vergleichende Studie mit Mumps- , Masern- , und Roeteln-Impfstoff allein oder zusammen mit Polio-Impfstoff appliziert]. Muenchner Medizinische Wochenschrift 1987;129(11):188-90.
  • Just 1987b {published data only}
  • Just M BR. Trivalent vaccines. A comparative study of the immunogenicity of two trivalent mumps-measles-rubella vaccines given with or without diphtheria-tetanus vaccine [Trivalente Impfstoffe. Vergleichende Studie zweier Mumps-Masern-Roeteln-Vakzinen in Kombination mit Diphtherie-Tetanus-Impfstoff]. Münchener Medizinische Wochenschrift 1987;129(23):446-7.
  • Kaaber 1990 {published data only}
  • Kaaber K, Samuelsson IS, Larsen SO. Reactions after MMR vaccination [Reaktioner efter MFR-vaccination]. Ugeskrift for Laeger 1990;152(23):1672-6.
  • Karim 2002 {published data only}
  • Karim Y, Masood A. Haemolytic uraemic syndrome following mumps, measles, and rubella vaccination. Nephrology, Dialysis, Transplantation 2002;17(5):941-2.
  • Kaye 2001 {published data only}
  • Kaye JA, del Mar C, Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001;322(7284):460-3.
  • Kazarian 1978 {published data only}
  • Kazarian EL, Gager WE. Optic neuritis complicating measles, mumps, and rubella vaccination. American Journal of Ophthalmology 1978;86(4):544-7.
  • Khalil 2005 {published data only}
  • Khalil MK, Al-Mazrou YY, AlHowasi MN, Al-Jeffri M. Measles in Saudi Arabia: from control to elimination. Annals of Saudi Medicine 2005;25(4):324-8.
  • Kiepiela 1991 {published data only}
  • Kiepiela P, Coovadia HM, Loening WE, Coward P, Botha G, Hugo J, et al.Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants. Bulletin of the World Health Organization 1991;69(2):221-7.
  • Kulkarni 2005 {published data only}
  • Kulkarni PS, Phadke MA, Jadhav SS, Kapre SV. No definitive evidence for L-Zagreb mumps strain associated aseptic meningitis: a review with special reference to the da Cunha study. Vaccine 2005;23(46-7):5286-8.
  • Kurtzke 1997 {published data only}
  • Kurtzke JF, Hyllested K, Arbuckle JD, Bronnum-Hansen H, Wallin MT, Heltberg A, et al.Multiple sclerosis in the Faroe Islands. 7. Results of a case control questionnaire with multiple controls. Acta Neurologica Scandinavica 1997;96(3):149-57.
  • Lee 1998 {published data only}
  • Lee JW, Melgaard B, Clements CJ, Kane M, Mulholland EK, Olive JM. Autism, inflammatory bowel disease, and MMR vaccine. Lancet 1998;351(9106):905; author reply 908-9.
  • Lee 2007 {published data only}
  • Lee KY, Lee HS, Hur JK, Kang JH, Lee BC. The changing epidemiology of hospitalized pediatric patients in three measles outbreaks. Journal of Infection 2007;54(2):167-72.
  • Lucena 2002 {published data only}
  • Lucena R, Gomes I, Nunes L, Cunha S, Dourado I, Teixeira Mda G, et al.Clinical and laboratory features of aseptic meningitis associated with measles-mumps-rubella vaccine [Caracteristicas clinicas e laboratoriais da meningite asseptica associada a vacina triplice viral]. Revista Panamericana de Salud Pública 2002;12(4):258-61.
  • Maekawa 1991 {published data only}
  • Maekawa K, Nozaki H, Fukushima K, Sugishita T, Kuriya N. Clinical analysis of measles, mumps and rubella vaccine meningitis - comparative study of mumps, mumps meningitis and MMR meningitis. Jikeikai Medical Journal 1991;38(4):361-8.
  • Maguire 1991 {published data only}
  • Maguire HC, Begg NT, Handford SG. Meningoencephalitis associated with MMR vaccine. CDR (London, England: review) 1991;1(6):R60-1.
  • Mantadakis 2010 {published data only}
  • Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. Journal of Pediatrics 2010;156(4):623-8.
  • Matter 1995 {published data only}
  • Matter L, Bally F, Germann D, Schopfer K. The incidence of rubella virus infections in Switzerland after the introduction of the MMR mass vaccination programme. European Journal of Epidemiology 1995;11(3):305-10.
  • Matter 1997 {published data only}
  • Matter L, Germann D, Bally F, Schopfer K. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. European Journal of Epidemiology 1997;13(1):61-6.
  • Meissner 2004 {published data only}
  • Meissner HC, Strebel PM, Orenstein WA. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 2004;114(4):1065-9.
  • Menniti-Ippolito 2007 {published data only}
  • Menniti-Ippolito F, Da Cas R, Bolli M, Capuano A, Saglioca L, Traversa G, et al.A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP 2007;14(3):98-102.
  • Miller 1983 {published data only}
  • Miller JR, Orgel HA, Meltzer EO. The safety of egg-containing vaccines for egg-allergic patients. Journal of Clinical Immunology 1983;71(6):568-73.
  • Miller 1993 {published data only}
  • Miller E, Goldacre M, Pugh S, Colville A, Farrington P, Flower A, et al.Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993;341(8851):979-82.
  • Miller 2001 {published data only}
  • Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Diseases in Childhood 2001;84(3):227-9.
  • Miller 2002 {published data only}
  • Miller E. MMR vaccine: review of benefits and risks. Journal of Infection 2002;44(1):1-6.
  • Min 1991 {published data only}
  • Min C-H, Lee J-H, Cho M-K. A study of immunogenicity of measles, mumps and rubella vaccine prepared from human diploid cell. Journal of the Korean Society for Microbiology 1991;26(5):487-91.
  • Minekawa 1974 {published data only}
  • Minekawa Y, Ueda S, Yamanishi K, Ogino T, Takahashi M. Studies on live rubella vaccine. V. Quantitative aspects of interference between rubella, measles and mumps viruses in their trivalent vaccine. Biken Journal 1974;17(4):161-7.
  • Mommers 2004 {published data only}
  • Mommers M, Weishoff-Houben M, Swaen GM, Creemers H, Freund H, Dott W, et al.Infant immunization and the occurrence of atopic disease in Dutch and German children: a nested case-control study. Pediatric Pulmonology 2004;38(4):329-34.
  • Mupere 2006 {published data only}
  • Mupere E, Karamagi C, Zirembuzi G, Grabowsky M, de Swart RL, Nanyunja M, et al.Measles vaccination effectiveness among children under 5 years of age in Kampala, Uganda. Vaccine 2006;24(19):4111-5.
  • Nalin 1999 {published data only}
  • Nalin D. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children (Infection 26). Infection 1999;27(2):134-5.
  • Nicoll 1998 {published data only}
  • Nicoll A, Elliman D, Ross E. MMR vaccination and autism 1998 [Erratum in: BMJ 1998 Mar 14;316(7134):796]. BMJ 1998;316(7133):715-6.
  • Noble 2003 {published data only}
  • Noble KK, Miyasaka K. Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine 2003;348(10):951-4; author reply 951-4.
  • O'Brien 1998 {published data only}
  • O'Brien SJ, Jones IG, Christie P. Autism, inflammatory bowel disease, and MMR vaccine. Lancet 1998;351(9106):906-7; author reply 908-9.
  • Ong 2006 {published data only}
  • Ong G, Hoon HB, Ong A, Chua LT, Kai CS, Tai GK. A 24-year review on the epidemiology and control of measles in Singapore, 1981-2004. Southeast Asian Journal of Tropical Medicine and Public Health 2006;37(1):96-101.
  • Patja 2000 {published data only}
  • Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatic Infectious Disease Journal 2000;19(12):1127-34.
  • Patja 2001 {published data only}
  • Patja A, Paunio M, Kinnunen E, Junttila O, Hovi T, Peltola H. Risk of Guillain-Barre syndrome after measles-mumps-rubella vaccination. Journal of Paediatrics 2001;138(2):250-4.
  • Pekmezovic 2004 {published data only}
  • Pekmezovic T, Jarebinski M, Drulovic J. Childhood infections as risk factors for multiple sclerosis: Belgrade case-control study. Neuroepidemiology 2004;23(6):285-8.
  • Peltola 1998 {published data only}
  • Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998;351(9112):1327-8.
  • Peltola 2007 {published data only}
  • Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clinical Infectious Diseases 2007;45(4):459-66.
  • Puvvada 1993 {published data only}
  • Puvvada L, Silverman B, Bassett C, Chiaramonte LT. Systemic reactions to measles-mumps-rubella vaccine skin testing. Pediatrics 1993;91(4):835-6.
  • Rajantie 2007 {published data only}
  • Rajantie J, Zeller B, Treutiger I, Rosthoj S. Vaccination associated thrombocytopenic purpura in children. Vaccine 2007;25(10):1838-40.
  • Ramos-Alvarez 1976 {published data only}
  • Ramos-Alvarez M, Bessudo L, Kenny MT, Jackson JE, Schwarz AJ. Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México 1976;33(4):875-86.
  • Roost 2004 {published data only}
  • Roost HP, Gassner M, Grize L, Wuthrich B, Sennhauser FH, Varonier HS, et al.Influence of MMR-vaccinations and diseases on atopic sensitization and allergic symptoms in Swiss schoolchildren. Pediatric Allergy and Immunology 2004;15(5):401-7.
  • Sabra 1998 {published data only}
  • Sabra A, Bellanti JA, Colon AR. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;352(9123):234-5.
  • Saraswathy 2009 {published data only}
  • Saraswathy TS, Zahrin HN, Norhashmimi H, Az-Ulhusna A, Zainah S, Rohani J. Impact of a measles elimination strategy on measles incidence in Malaysia. Southeast Asian Journal of Tropical Medicine and Public Health 2009;40(4):742-7.
  • Scarpa 1990 {published data only}
  • Scarpa B, Masia G, Contu P, Origa P, Sanna CM, Pintor C, et al.Trivalent vaccine against measles, rubella and parotitis: clinic and serological evaluation [Vaccino trivalente contro morbillo, rosolia e parotite : valutazione clinica e sierologica]. Giornale di Malattie Infettive e Parassitarie 1990;42(6):344-7.
  • Schaffzin 2007 {published data only}
  • Schaffzin JK, Pollock L, Schulte C, Henry K, Dayan G, Blog D, et al.Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics 2007;120(4):e862-8.
  • Schettini 1989 {published data only}
  • Schettini F, Manzionna MM, De Mattia D, Amendola F, Di Bitonto G. Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps [Valutazione clinico-immunologica di un vaccino trivalente contro morbillo, rosolia e parotite]. Minerva Pediatrica 1989;41(3):117-22.
  • Schettini 1990 {published data only}
  • Schettini F, Manzionna MM, De Mattia D, Amendola F, Di Bitonto G. The clinico-immunological evaluation of a bivalent vaccine against measles and rubella [Valutazione clinico-immunologica di un vaccino bivalente contro morbillo e rosolia]. Minerva Pediatrica 1990;42(12):531-6.
  • Schmid 2008 {published data only}
  • Schmid D, Holzmann H, Alfery C, Wallenko H, Popow-Kraupp TH, Allerberger F. Mumps outbreak in young adults following a festival in Austria, 2006. Euro Surveillance: European Communicable Disease Bulletin 2008;13(7):8042 [pii].
  • Schwarz 2010 {published data only}
  • Schwarz NG, Bernard H, Melnic A, Bucov V, Caterinciuc N, an der Heiden M, et al.Mumps outbreak in the Republic of Moldova, 2007-2008. Pediatric Infectious Disease Journal 2010;29(8):703-6.
  • Schwarzer 1998 {published data only}
  • Schwarzer S, Reibel S, Lang AB, Struck MM, Finkel B, Gerike E, et al.Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine 1998;16(2-3):298-304.
  • Seagroatt 2003 {published data only}
  • Seagroatt V, Goldacre MJ. Crohn's disease, ulcerative colitis, and measles vaccine in an English population, 1979-1998. Journal of Epidemiology and Community Health 2003;57(11):883-7.
  • Sharma 2004 {published data only}
  • Sharma MK, Bhatia V, Swami HM. Outbreak of measles amongst vaccinated children in a slum of Chandigarh. Indian Journal of Medical Sciences 2004;58(2):47-53.
  • Shinefield 2002 {published data only}
  • Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, et al.Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatric Infectious Disease Journal 2002;21(6):555-61.
  • Spitzer 2001 {published data only}
  • Spitzer WO. A sixty day war of words: is MMR linked to autism?. Adverse Drug Reactions and Toxicological Reviews 2001;20(1):47-55.
  • Stetler 1985 {published data only}
  • Stetler HC, Mullen JR, Brennan JP, Orenstein WA, Bart KJ, Hinman AR. Adverse events following immunization with DTP vaccine. Developments in Biological Standardization 1985;61:411-21.
  • Stokes 1967 {published data only}
  • Stokes JJ. Studies on active immunization in measles, mumps and rubella. Johns Hopkins Medical Journal 1967;121(5):314-28.
  • Stratton 1994 {published data only}
  • Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994;271(20):1602-5.
  • Sugiura 1982 {published data only}
  • Sugiura A, Ohtawara M, Hayami M, Hisiyama M, Shishido A, Kawana R, et al.Field trial of trivalent measles-rubella-mumps vaccine in Japan. Journal of Infectious Diseases 1982;146(5):709.
  • Ueda 1995 {published data only}
  • Ueda K, Miyazaki C, Hidaka Y, Okada K, Kusuhara K, Kadoya R. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet 1995;346(8976):701-2.
  • Vesikari 1979 {published data only}
  • Vesikari T, Elo O. Vaccination against measles, mumps and rubella--together or separately? [Tuhkarokon, sikotaudin ja vihurirokon torjunta--yhdessa vai erikseen?]. Duodecim 1979;95(9):527-9.
  • Vesikari 1984 {published data only}
  • Vesikari T, Ala-Laurila EL, Heikkinen A, Terho A, D'Hondt E, Andre FE. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children. American Journal of Diseases in Children 1984;138(9):843-7.
  • Wakefield 1998 {published data only}
  • Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al.Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351(9103):637-41.
  • Wakefield 1999a {published data only}
  • Wakefield AJ, Montgomery SM. Autism, viral infection and measles-mumps-rubella vaccination. Israel Medical Association Journal 1999;1(3):183-7.
  • Wakefield 1999b {published data only}
  • Wakefield AJ. MMR vaccination and autism. Lancet 1999;354(9182):949-50.
  • Wakefield 2000 {published data only}
  • Wakefield AJ, Montgomery SM. Measles, mumps, rubella vaccine: through a glass, darkly. Adverse Drug Reactions and Toxicological Reviews 2000;19(4):265-83; discussion 284-92.
  • Walters 1975 {published data only}
  • Walters VW, Miller SA, Jackson JE, Kenny MT. A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics 1975;14(10):928-33.
  • Wilson 2003 {published data only}
  • Wilson K, Mills E, Ross C, McGowan J, Jadad A. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Archives of Pediatric and Adolescent Medicine 2003;157(7):628-34.
  • Woyciechowska 1985 {published data only}
  • Woyciechowska JL, Dambrozia J, Leinikki P, Shekarchi C, Wallen W, Sever J, et al.Viral antibodies in twins with multiple sclerosis. Neurology 1985;35(8):1176-80.
  • Yamashiro 1998 {published data only}
  • Yamashiro Y, Walker-Smith JA, Shimizu T, Oguchi S, Ohtsuka Y. Measles vaccination and inflammatory bowel disease in Japanese children. Journal of Pediatric Gastroenterology and Nutrition 1998;26(2):238.
  • Yu 2007 {published data only}
  • Yu X, Wang S, Guan J, Mahemuti, Purhati, Gou A, et al.Analysis of the cause of increased measles incidence in Xinjiang, China in 2004. Pediatric Infectious Disease Journal 2007;26(6):513-8.
  • References to studies awaiting assessment
  • Arenz 2005 {published data only}
  • Arenz S, Schmitt HJ, Tischer A, von Kries R. Effectiveness of measles vaccination after household exposure during a measles outbreak: a household contact study in Coburg, Bavaria. Pediatric Infectious Disease Journal 2005;24(8):697-9.
  • Barlow 2001 {published data only}
  • Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, et al.The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine 2001;345(9):656-61.
  • Barrabeig 2011 {published data only}
  • Barrabeig I, Rovira A, Rius C, Munoz P, Soldevila N, Batalla J, et al.Effectiveness of measles vaccination for control of exposed children. Pediatric Infectious Disease Journal 2011;30(1):78-80.
  • Benke 2004 {published data only}
  • Benke G, Abramson M, Raven J, Thien FC, Walters EH. Asthma and vaccination history in a young adult cohort. Australian and New Zealand Journal of Public Health 2004;28(4):336-8.
  • Cohen 2007 {published data only}
  • Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, et al.Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerging Infectious Diseases 2007;13(1):12-7.
  • da Silveira 2002 {published data only}
  • da Silveira CM, Kmetzsch CI, Mohrdieck R, Sperb AF, Prevots DR. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology 2002;31(5):978-82.
  • Dominguez 2010 {published data only}
  • Dominguez A, Torner N, Castilla J, Batalla J, Godoy P, Guevara M, et al.Mumps vaccine effectiveness in highly immunized populations. Vaccine 2010;28(20):3567-70.
  • Huang 2009 {published data only}
  • Huang AS, Cortese MM, Curns AT, Bitsko RH, Jordan HT, Soud F, et al.Risk factors for mumps at a university with a large mumps outbreak. Public Health Reports 2009;124(3):419-26.
  • Jick 2010 {published data only}
  • Jick H, Hagberg KW. Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Vaccine 2010;28(29):4588-92.
  • Mallol-Mesnard 2007 {published data only}
  • Mallol-Mesnard N, Menegaux F, Auvrignon A, Auclerc M-F, Bertrand Y, Nelken B, et al.Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). International Journal of Epidemiology 2007;36(1):110-6.
  • Marin 2008 {published data only}
  • Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students - Iowa, 2006. Vaccine 2008;26(29-30):3601-7.
  • Schultz 2008 {published data only}
  • Schultz ST, Klonoff-Cohen HS, Wingard DL, Akshoomoff NA, Macera CA, Ji M. Acetaminophen (paracetamol) use, measles-mumps-rubella vaccination, and autistic disorder: the results of a parent survey. Autism 2008;12(3):293-307.
  • Sheppeard 2009 {published data only}
  • Sheppeard V, Forssman B, Ferson MJ, Moreira C, Campbell-Lloyd S, Dwyer DE, et al.Vaccine failures and vaccine effectiveness in children during measles outbreaks in New South Wales, March-May 2006. Communicable Diseases Intelligence 2009;33(1):21-6.
  • So 2008 {published data only}
  • So JS, Go UY, Lee DH, Park KS, Lee JK. Epidemiological investigation of a measles outbreak in a preschool in Incheon, Korea, 2006. Journal of Preventive Medicine and Public Health 2008;41(3):153-8.
  • Svanstrom 2010 {published data only}
  • Svanstrom H, Callreus T, Hviid A. Temporal data mining for adverse events following immunization in nationwide Danish healthcare databases. Drug Safety 2010;33(11):1015-25.
  • Wichmann 2007 {published data only}
  • Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, et al.Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal 2007;26(9):782-6.
  • Additional references
  • Briss 1994
  • Briss PA, Fehrs LJ, Parker RA, Wright PF, Sannella EC, Hutcheson RH, et al.Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. Journal of Infectious Diseases 1994;169(1):77-82.
  • CDC 1997
  • Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. Morbidity and Mortality Weekly Report 1997;46:RR-19.
  • Cortese 2008
  • Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM, et al.Mumps vaccine performance among university students during a mumps outbreak. Clinical Infectious Diseases 2008;46(8):1172-80.
  • Dayan 2008b
  • Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?. Clinical Infectious Diseases 2008;47(11):1458-67.
  • Farrington 2004
  • Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 2004;22(15-16):2064-70.
  • Flaherty 2011
  • Flaherty DK. The vaccine-autism connection: a public health crisis caused by unethical medical practices and fraudulent science. Annals of Pharmacotherapy 2011;45(10):1302-4.
  • Gay 1997
  • Gay N, Miller E, Hesketh L, Morgan-Capner P, Ramsay M, Cohen B, et al.Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Communicable Disease Report. CDR Review 1997;7(2):R21-6.
  • Hersh 1991
  • Hersh BS, Fine PE, Kent WK, Cochi SL, Kahn LH, Zell ER, et al.Mumps outbreak in a highly vaccinated population. Journal of Pediatrics 1991;119(2):187-93.
  • Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration. Available from www.cochrane-handbook.org.. Chichester: Wiley-Blackwell, 2011.
  • Hilton 2007
  • Hilton S, Hunt K, Petticrew M. MMR: marginalised, misrepresented and rejected? Autism: a focus group study. Archives of Disease in Childhood 2007;92(4):322-7.
  • Jefferson 1999
  • Jefferson T, Demicheli V. Relation between experimental and non-experimental study designs. HB vaccines: a case study. Journal of Epidemiology and Community Health 1999;53(1):51-4.
  • Khan 2001
  • Khan SK, ter Riet G, Popay J, Nixon J, Kleijnen J. Stage II Conducting the review: Phase 5: Study quality assessment. In: Khan SK, ter Riet G, Glanville G, Sowden AJ, Kleijnen J editor(s). Undertaking Systematic Reviews of Research on Effectiveness. CDR's guidance for carrying out or commissioning reviews. CRD Report No 4. 2nd Edition. York: NHS Centre for Reviews and Dissemination, University of York, 2001.
  • Kohl 2001
  • Kohl KS, Bonhoeffer J. Safety reporting in clinical trials. JAMA 2001;285(16):2076-7; author reply 2077-8.
  • Kreidl 2003
  • Kreidl P, Morosetti G. Must we expect an epidemic of measles in the near future in Southern Tyrol? [Mussen wir in naher Zukunft mit einer Masernepidemie in Sudtirol rechnen?]. Wiener Klinische Wochenschrift 2003;115(Suppl):355-60.
  • Last 2001
  • Last J. A Dictionary of Epidemiology. 4th Edition. Oxford: Oxford University Press, 2001.
  • Murch 2004
  • Murch SH, Anthony A, Casson DH, Malik M, Berelowitz M, Dhillon AP, et al.Retraction of an interpretation. Lancet 2004; Vol. 363, issue 9411:750.
  • Offit 2003
  • Offit PA, Coffin SE. Communicating science to the public: MMR vaccine and autism. Vaccine 2003;22(1):1-6.
  • Orenstein 1985
  • Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, et al.Field evaluation of vaccine efficacy. Bulletin of the World Health Organization 1985;63(6):1055-68.
  • Peltola 2000
  • Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA 2000;284(20):2643-7.
  • Plotkin 1965
  • Plotkin SA, Cornfeld D, Ingalls TH. Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus. American Journal of Diseases in Children 1965;110(4):381-9.
  • Plotkin 1973
  • Plotkin SA, Farquhar JD, Ogra PL. Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States. JAMA 1973;225(6):585-90.
  • Plotkin 1999a
  • Plotkin SA. Rubella vaccine. In: Plotkin SA, Orenstein WA editor(s). Vaccines. Philadelphia: WB Saunders, 1999:409-39.
  • Plotkin 1999b
  • Plotkin SA, Wharton M. Mumps vaccine. In: Plotkin SA, Orenstein WA editor(s). Vaccines. Philadelphia: WB Saunders, 1999:267-92.
  • Redd 1999
  • Redd SC, Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, Orenstein WA editor(s). Vaccines. Philadelphia: WB Saunders, 1999:222-66.
  • Smith 2008
  • Smith MJ, Ellenberg SS, Bell LM, Rubin DM. Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR immunization rates in the United States. Pediatrics 2008;121(4):e836-43.
  • Steffenburg 1989
  • Steffenburg S, Gillberg C, Hellgren L, Andersson L, Gillberg IC, Jakobsson G, et al.A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. Journal of Child Psychology and Psychiatry and Allied Disciplines 1989;30(3):405-16.
  • Strebel 2004
  • Strebel PM, Henao-Restrepo AM, Hoekstra E, Olive JM, Papania MJ, Cochi SL. Global measles elimination efforts: the significance of measles elimination in the United States. Journal of Infectious Diseases 2004;189(Suppl 1):251-7.
  • The Editors of The Lancet 2010
  • The Editors of The Lancet. Retraction - Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 2010; Vol. 375, issue 9713:445.
  • Vandermeulen 2004
  • Vandermeulen C, Roelants M, Vermoere M, Roseeuw K, Goubau P, Hoppenbrouwers K. Outbreak of mumps in a vaccinated child population: a question of vaccine failure?. Vaccine 2004;22(21-22):2713-6.
  • Watson 1998
  • Watson JC, Redd SC, Rhodes PH, Hadler SC. The interruption of transmission of indigenous measles in the United States during 1993. Pediatric Infectious Disease Journal 1998;17(5):363-6; discussion 366-7.
  • Wells 2000
  • Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses. Available from URL: http://www.Iri.ca/programs/ceu/oxford.htm 2000.
  • WHO 1999
  • World Health Organization. Measles. Progress towards global control and regional elimination, 1998-1999. Weekly Epidemiology Records 1999;74(50):429-34.
  • WHO 2009
  • World Health Organization. Measles vaccines: WHO position paper. Weekly Epidemiological Record 2009;84(35):349-60.
  • WHO 2011
  • World Health Organization. Immunization schedules by disease covered by antigens within age range, selection centre: Last update: 22 July 2011 (data as of 20-July-2011) Next overall update: August 2011. http://apps.who.int/immunization_monitoring/en/globalsummary/diseaseselect.cfm 2011 (accessed 13 September 2011).
  • References to other published versions of this review
  • Demicheli 2005
  • Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004407.pub2]